Bicycle Therapeutics (BCYC) Other Non-Current Assets (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Other Non-Current Assets came in at $12.7 million in Q2 2026, down 8.26% YoY from $13.8 million in Q2 2025, and down 2.49% on a QoQ basis from $13.0 million in Q1 2026.
Analysis
Bicycle Therapeutics (BCYC) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Other Non-Current Assets data on file, last reported at $12.7 million in Q2 2026.
- Quarterly Other Non-Current Assets fell 8.26% year-over-year to $12.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $12.7 million (down 8.26% YoY) and the FY2025 annual result came in at $12.8 million, up 15.63% from the prior year.
- Other Non-Current Assets slipped to $12.7 million in Q2 2026, from $13.0 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $13.8 million in Q2 2025 to a low of $4.2 million in Q1 2022.
- A 5-year average of $9.5 million and a median of $10.3 million in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets jumped 151.69% — and 2024, when it sank 45.83%.
- Tracing BCYC's Other Non-Current Assets over 5 years: stood at $8.5 million in 2022, then tumbled by 31.52% to $5.8 million in 2023, then jumped by 91.19% to $11.1 million in 2024, then increased by 15.63% to $12.8 million in 2025, then declined by 1.07% to $12.7 million in 2026.
- The last three Other Non-Current Assets figures came in at $12.7 million (Q2 2026), $13.0 million (Q1 2026), and $12.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Bicycle Therapeutics | 297.72 Mn | 297.72 Mn | - | 12.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.67 Mn |
| Mar 31, 2026 | 12.99 Mn |
| Dec 31, 2025 | 12.81 Mn |
| Sep 30, 2025 | 13.71 Mn |
| Jun 30, 2025 | 13.81 Mn |
| Mar 31, 2025 | 12.36 Mn |
| Dec 31, 2024 | 11.07 Mn |
| Sep 30, 2024 | 9.94 Mn |
| Jun 30, 2024 | 6.58 Mn |
| Mar 31, 2024 | 6.37 Mn |
| Dec 31, 2023 | 5.79 Mn |
| Sep 30, 2023 | 5.45 Mn |
| Jun 30, 2023 | 12.15 Mn |
| Mar 31, 2023 | 10.57 Mn |
| Dec 31, 2022 | 8.46 Mn |
| Sep 30, 2022 | 6.16 Mn |
| Jun 30, 2022 | 5.10 Mn |
| Mar 31, 2022 | 4.20 Mn |
| Dec 31, 2021 | 3.45 Mn |
| Sep 30, 2021 | 2.78 Mn |